Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is
central to long-term control of the current pandemic. Despite our rapidly advancing …
central to long-term control of the current pandemic. Despite our rapidly advancing …
SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants
D Martínez-Flores, J Zepeda-Cervantes… - Frontiers in …, 2021 - frontiersin.org
Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is
caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose …
caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose …
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
The durability of infection-induced SARS-CoV-2 immunity has major implications for
reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B …
reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B …
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10–15 d
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS …
after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS …
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly
infectious respiratory virus which is responsible for the coronavirus disease 2019 (COVID …
infectious respiratory virus which is responsible for the coronavirus disease 2019 (COVID …
Humoral responses and serological assays in SARS-CoV-2 infections
Y Galipeau, M Greig, G Liu, M Driedger… - Frontiers in …, 2020 - frontiersin.org
In December 2019, the novel betacoronavirus Severe Acute Respiratory Disease
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …
Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection
KHD Crawford, AS Dingens, R Eguia… - The Journal of …, 2021 - academic.oup.com
Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) develop neutralizing antibodies that target the viral spike protein. In this study, we …
2) develop neutralizing antibodies that target the viral spike protein. In this study, we …
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
CJ Reynolds, L Swadling, JM Gibbons, C Pade… - Science …, 2020 - science.org
Understanding the nature of immunity following mild/asymptomatic infection with SARS-CoV-
2 is crucial to controlling the pandemic. We analyzed T cell and neutralizing antibody …
2 is crucial to controlling the pandemic. We analyzed T cell and neutralizing antibody …
Sex differences in immunity
NM Wilkinson, HC Chen, MG Lechner… - Annual review of …, 2022 - annualreviews.org
Strong epidemiological evidence now exists that sex is an important biologic variable in
immunity. Recent studies, for example, have revealed that sex differences are associated …
immunity. Recent studies, for example, have revealed that sex differences are associated …
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
COVID-19 vaccine design and vaccination rollout need to take into account a detailed
understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 …
understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 …